Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAITS Programme: Precision medicine trials for adults treated in critical care units
ISRCTN82395639Phase 4Active, not recruiting
- Sponsor
- Accord Healthcare
- Start
- Jan 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of budesonide, baricitinib and imatinib in critical illness (5 arms), sponsored by Accord Healthcare. Primary endpoints: Organ support-free days during first 21 days and Trait-specific intermediate adaptive endpoint. Started Jan 2024; status: active, not recruiting.
02
Drugs
03
Conditions
critical illness
Beyond the preview
Go deeper on ISRCTN82395639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82395639.